BIOVERATIV INC (NASDAQ: BIVV) and Achaogen (NASDAQ:AKAO) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitabiliy, analyst recommendations, dividends, institutional ownership and risk.
Analyst Ratings
This is a breakdown of current recommendations and price targets for BIOVERATIV INC and Achaogen, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BIOVERATIV INC | 1 | 7 | 5 | 1 | 2.43 |
| Achaogen | 0 | 1 | 8 | 0 | 2.89 |
BIOVERATIV INC presently has a consensus price target of $58.17, suggesting a potential downside of 0.99%. Achaogen has a consensus price target of $25.88, suggesting a potential upside of 46.10%. Given Achaogen’s stronger consensus rating and higher probable upside, analysts plainly believe Achaogen is more favorable than BIOVERATIV INC.
Profitability
This table compares BIOVERATIV INC and Achaogen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BIOVERATIV INC | N/A | N/A | N/A |
| Achaogen | -281.88% | -118.04% | -63.79% |
Institutional and Insider Ownership
90.4% of BIOVERATIV INC shares are owned by institutional investors. Comparatively, 69.7% of Achaogen shares are owned by institutional investors. 13.8% of Achaogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares BIOVERATIV INC and Achaogen’s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | EBITDA | Earnings Per Share | Price/Earnings Ratio | |
| BIOVERATIV INC | $1.03 billion | 6.17 | $451.00 million | N/A | N/A |
| Achaogen | $43.39 million | 14.63 | -$54.98 million | ($3.16) | -5.60 |
BIOVERATIV INC has higher revenue and earnings than Achaogen.
Summary
BIOVERATIV INC beats Achaogen on 7 of the 12 factors compared between the two stocks.
About BIOVERATIV INC
Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person’s blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).
About Achaogen
Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company’s Early Development programs include C-Scape and LpxC.
Receive News & Ratings for BIOVERATIV INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOVERATIV INC and related companies with MarketBeat.com's FREE daily email newsletter.
